Patients with alcoholism, anxiety and two copies of the CYP3A4*1 allele may have an increased response to alprazolam, as measured by changes in HAMA scores, as compared to patients with one copy of the *1 allele in combination with one copy of the *22 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to alprazolam.